Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Health Services Research
Published in: BMC Health Services Research 1/2018

Open Access 01-12-2018 | Research article

In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital

Authors: Sabine Engler-Hüsch, Thomas Heister, Nico T Mutters, Jan Wolff, Klaus Kaier

Published in: BMC Health Services Research | Issue 1/2018

Login to get access

Abstract

Background

Antibiotic resistance is a challenge in the management of infectious diseases and can cause substantial cost. Even without the onset of infection, measures must be taken, as patients colonized with multi-drug resistant (MDR) pathogens may transmit the pathogen. We aim to quantify the cost of community-acquired MDR colonizations using routine data from a German teaching hospital.

Methods

All 2006 cases of documented MDR colonization at hospital admission recorded from 2011 to 2014 are matched to 7917 unexposed controls with the same primary diagnosis. Cases with an onset MDR infection are excluded from the analysis. Routine data on costs per case is analysed for three groups of MDR bacteria: Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), and multidrug-resistant gram-negative bacteria (MDR-GN). Multivariate analyses are conducted to adjust for potential confounders.

Results

After controlling for main diagnosis group, age, sex, and Charlson Comorbidity Index, MDR colonization is associated with substantial additional costs from the healthcare perspective (€1480.9, 95%CI €1286.4–€1675.5). Heterogeneity between pathogens remains. Colonization with MDR-GN leads to the largest cost increase (€1966.0, 95%CI €1634.6–€2297.4), followed by MRSA with €1651.3 (95%CI €1279.1–€2023.6), and VRE with €879.2 (95%CI €604.1–€1154.2). At the same time, MDR-GN is associated with additional reimbursements of €887.8 (95%CI €722.1–€1053.6), i.e. costs associated with MDR-colonization exceed reimbursement.

Conclusions

Even without the onset of invasive infection, documented MDR-colonization at hospital admission is associated with increased hospital costs, which are not fully covered within the German DRG-based hospital payment system.
Appendix
Available only for authorised users
Literature
1.
2.
Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol. 2001 Feb;22(02):99–104.CrossRef
3.
Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55(6):807–15.CrossRef
4.
Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ. 2009;10(3):287–97.CrossRef
5.
6.
Ibert F, Eckstein M, Günther F, Mutters NT. The relationship between subjective perception and the psychological effects of patients in spatial isolation. GMS Hyg Infect Control. 2017;12:Doc11.PubMedPubMedCentral
7.
Cluzet VC, Gerber JS, Nachamkin I, Metlay JP, Zaoutis TE, Davis MF, et al. Duration of colonization and determinants of earlier clearance of colonization with methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2015;60(10):1489–96.CrossRef
8.
Graves N, Harbarth S, Beyersmann J, Barnett A, Halton K, Cooper B. Estimating the cost of health care–associated infections: mind your p’s and q’s. Clin Infect Dis. 2010;50(7):1017–21.CrossRef
9.
10.
Mutters NT, Günther F, Frank U, Mischnik A. Costs and possible benefits of a two-tier infection control management strategy consisting of active screening for multidrug-resistant organisms and tailored control measures. J Hosp Infect. 2016;93(2):191–6.CrossRef
11.
Quentin W, Geissler A, Scheller-Kreinsen D, Busse R. DRG-type hospital payment in Germany: the G-DRG system. Euro Obs. 2010;12(3):4–6.
12.
Braun J-P, Bause H, Bloos F, Geldner G, Kastrup M, Kuhlen R, et al. Peer reviewing critical care: a pragmatic approach to quality management. GMS Ger Med Sci. 2010;8:Doc23 ISSN 1612–3174.PubMed
13.
Gutmann A, Kaier K, Sorg S, von zur Mühlen C, Siepe M, Moser M, et al. Analysis of the additional costs of clinical complications in patients undergoing transcatheter aortic valve replacement in the German health care system. Int J Cardiol. 2015;179:231–7.CrossRef
14.
Reinöhl J, Gutmann A, Kollum M, von zur Mühlen C, Baumbach H, Avlar M, et al. Transfemoral aortic valve implantation: bleeding events, related costs and outcomes. J Thromb Thrombolysis. 2013;35(4):469–75.CrossRef
15.
Vogl M. Assessing DRG cost accounting with respect to resource allocation and tariff calculation: the case of Germany. Health Econ Rev. 2012;2(1):15.CrossRef
16.
Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2012;17(46).
17.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRef
18.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data. Med Care. 2005;43(11):1130–9.CrossRef
19.
Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9(4):197–204.CrossRef
20.
Griswold M. Analyzing health care costs: a comparison of statistical methods motivated by Medicare colorectal Cancer charges. Biostatistics. 2004;1(1):1–23.
21.
22.
Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12(2):308.
23.
Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay. J Hosp Infect. 2013;85(1):54–9.CrossRef
24.
Tran K, Bell C, Stall N, Tomlinson G, McGeer A, Morris A, et al. The effect of hospital isolation precautions on patient outcomes and cost of care: a multi-site, retrospective, propensity score-matched cohort study. J Gen Intern Med. 2017;32(3):262–8.CrossRef
25.
Robinson J. Colonization and infection of the respiratory tract: what do we know? Paediatr Child Health. 2004;9(1):21–4.CrossRef
26.
Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368(24):2255–65.CrossRef
27.
Nelson RE, Samore MH, Smith KJ, Harbarth S, Rubin MA. Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers. Clin Microbiol Infect. 2010;16(12):1740–6.CrossRef
28.
Jung E, Byun S, Lee H, Moon SY, Lee H. Vancomycin-resistant enterococcus colonization in the intensive care unit: clinical outcomes and attributable costs of hospitalization. Am J Infect Control. 2014;42(10):1062–6.CrossRef
29.
Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36(2):131–9.CrossRef
30.
Mutters NT, Frank U. Sources of systematic errors in the epidemiology of vancomycin-resistant enterococci. Infection. 2013;41(2):305–10.CrossRef
31.
Mutters NT, Brooke RJ, Frank U, Heeg K. Low risk of apparent transmission of vancomycin-resistant enterococci from bacteraemic patients to hospitalized contacts. Am J Infect Control. 2013;41(9):778–81.CrossRef
32.
Wolkewitz M, Beyersmann J, Gastmeier P, Schumacher M. Efficient risk set sampling when a time-dependent exposure is present. Methods Inf Med. 2009;48(5):438–43.CrossRef
Metadata
Title
In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital
Authors
Sabine Engler-Hüsch
Thomas Heister
Nico T Mutters
Jan Wolff
Klaus Kaier
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2018
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-018-3549-0

Other articles of this Issue 1/2018

BMC Health Services Research 1/2018 Go to the issue

Research article

What is behind high turnover: a questionnaire survey of hospital nursing care workers in Shanghai, China

Research article

Determinants of new drugs prescription in the Swiss healthcare market

Research article

A prospective observational study of drug therapy problems in medical ward of a referral hospital in northeast Ethiopia

Research article

A before-after study of hospital use in two frail populations receiving different home-based services over the same time in Vancouver, Canada

Research article

Disabled people’s experiences of accessing reasonable adjustments in hospitals: a qualitative study

Study protocol

Implementing universal Lynch syndrome screening (IMPULSS): protocol for a multi-site study to identify strategies to implement, adapt, and sustain genomic medicine programs in different organizational contexts